@article{54895d87fc74488ba5fd5ce1fa81ffac,
title = "Insulin resistance intervention after stroke trial of pioglitazone: Is this perhaps the end of the beginning?",
keywords = "diabetes mellitus, heart failure, insulin, pioglitazone, stroke",
author = "George Ntaios and Kent, {Thomas A.}",
note = "Funding Information: Dr Kent was funded partly by grants R21NS084290 and R01NS094535 from the National Institute of Neurological Disorders and Stroke. He is a member of and owns shares in Acelerox, LLC to commercialize the medical use of carbon nanoantioxidants. Dr Ntaios reports no conflicts.",
year = "2016",
month = jul,
day = "1",
doi = "10.1161/STROKEAHA.116.013230",
language = "English (US)",
volume = "47",
pages = "1962--1964",
journal = "Stroke",
issn = "0039-2499",
publisher = "American Heart Association",
number = "7",
}